Show simple item record

dc.contributor.authorChaudhuri, Shomesh E
dc.contributor.authorBen Chaouch, Zied
dc.contributor.authorHauber, Brett
dc.contributor.authorMange, Brennan
dc.contributor.authorZhou, Mo
dc.contributor.authorChristopher, Stephanie
dc.contributor.authorBardot, Dawn
dc.contributor.authorSheehan, Margaret
dc.contributor.authorDonnelly, Anne
dc.contributor.authorMcLaughlin, Lauren
dc.contributor.authorCaldwell, Brittany
dc.contributor.authorBenz, Heather L
dc.contributor.authorHo, Martin
dc.contributor.authorSaha, Anindita
dc.contributor.authorGwinn, Katrina
dc.contributor.authorSheldon, Murray
dc.contributor.authorLo, Andrew W
dc.date.accessioned2026-02-18T15:47:30Z
dc.date.available2026-02-18T15:47:30Z
dc.date.issued2025-09-03
dc.identifier.urihttps://hdl.handle.net/1721.1/164905
dc.description.abstractA fixed one-sided significance level of 5% is commonly used to interpret the statistical significance of randomized clinical trial (RCT) outcomes. While it is necessary to reduce the false positive rate, the threshold used could be chosen quantitatively and transparently to specifically reflect patient preferences regarding benefit–risk tradeoffs as well as other considerations. How can patient preferences be explicitly incorporated into RCTs in Parkinson’s disease (PD), and what is the impact on statistical thresholds for device approval? In this analysis, we apply Bayesian decision analysis (BDA) to PD patient preference scores elicited from survey data. BDA allows us to choose a sample size (𝑛) and significance level (𝛼) that maximizes the overall expected value to patients of a balanced two-arm fixed-sample RCT, where the expected value is computed under both null and alternative hypotheses. For PD patients who had previously received deep brain stimulation (DBS) treatment, the BDA-optimal significance levels fell between 4.0% and 10.0%, similar to or greater than the traditional value of 5%. Conversely, for patients who had never received DBS, the optimal significance level ranged from 0.2% to 4.4%. In both of these populations, the optimal significance level increased with the severity of the patients’ cognitive and motor function symptoms. By explicitly incorporating patient preferences into clinical trial designs and the regulatory decision-making process, BDA provides a quantitative and transparent approach to combine clinical and statistical significance. For PD patients who have never received DBS treatment, a 5% significance threshold may not be conservative enough to reflect their risk-aversion level. However, this study shows that patients who previously received DBS treatment present a higher tolerance to accept therapeutic risks in exchange for improved efficacy which is reflected in a higher statistical threshold.en_US
dc.language.isoen
dc.publisherTaylor & Francisen_US
dc.relation.isversionofhttps://doi.org/10.1080/10543406.2023.2170400en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceTaylor & Francisen_US
dc.titleUse of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s diseaseen_US
dc.typeArticleen_US
dc.identifier.citationChaudhuri, S. E., Ben Chaouch, Z., Hauber, B., Mange, B., Zhou, M., Christopher, S., … Lo, A. W. (2025). Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s disease. Journal of Biopharmaceutical Statistics, 35(5), 981–1000.en_US
dc.contributor.departmentSloan School of Managementen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Electrical Engineering and Computer Scienceen_US
dc.contributor.departmentMassachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratoryen_US
dc.relation.journalJournal of Biopharmaceutical Statisticsen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2026-02-18T15:40:24Z
dspace.orderedauthorsChaudhuri, SE; Ben Chaouch, Z; Hauber, B; Mange, B; Zhou, M; Christopher, S; Bardot, D; Sheehan, M; Donnelly, A; McLaughlin, L; Caldwell, B; Benz, HL; Ho, M; Saha, A; Gwinn, K; Sheldon, M; Lo, AWen_US
dspace.date.submission2026-02-18T15:40:31Z
mit.journal.volume35en_US
mit.journal.issue5en_US
mit.licensePUBLISHER_CC
mit.metadata.statusAuthority Work and Publication Information Neededen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record